Prostate cancer is the most frequent nonskin cancer and second most common cause of
cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with …

Inactivation of the RB1 tumor suppressor gene is common in several types of therapy-
resistant cancers, including metastatic castration-resistant prostate cancer, and predicts poor …

Simple Summary The molecular progression of prostate cancer is complex and elusive.
Biological research relies heavily on in vitro and in vivo models that can be used to examine …

Prostate cancers (PCs) with loss of the potent tumor suppressors TP53 and RB1 exhibit poor
outcomes. TP53 and RB1 also influence cell plasticity and are frequently lost in PCs with …

Purpose: RB1 mutations and loss of retinoblastoma (Rb) expression represent consistent
but not entirely invariable hallmarks of small cell lung cancer (SCLC). The prevalence and …

Purpose: Previous sequencing studies revealed that alterations of genes associated with
DNA damage response (DDR) are enriched in men with metastatic castration-resistant …

Loss of the retinoblastoma (RB) tumor suppressor protein is a critical step in reprogramming
biological networks that drive cancer progression, although mechanistic insight has been …

The interaction of RB with chromatin is key to understanding its molecular functions. Here,
for first time, we identify the full spectrum of chromatin-bound RB. Rather than exclusively …

The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …

The retinoblastoma tumor suppressor gene (RB1) plays a critical role in coordinating
multiple pathways that impact cancer initiation, disease progression, and therapeutic …